Updates on the treatment of MDS

Sangmin Lee, MD, Weill Cornell Medicine, New York, NY, outlines new treatments for high-risk myelodysplastic syndromes (MDS). The current standard of care includes hypomethylating agents and recent advancements include oral decitabine and cedazuridine, which represent a convenient option for patients. Venetoclax, which has been approved in acute myeloid leukemia (AML) and hypomethylating agents, as well as cemiplimab or magrolimab with azacytidine, are additional promising treatment regimens in patients with high-risk MDS. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

• #education
• #speaker_sangmin_lee
• #institution_weill_cornell_medicine
• #event_llm_2021
• #format_interview
• #subject_myelodysplastic_syndromes
• #field_field_clinical_practice
• #field_treatment
• #field_immuno_oncology
• #medicines_antibodies
• #medicines_decitabine
• #medicines_cedazuridine
• #medicines_venetoclax
• #medicines_cemiplimab
• #medicines_magrolimab
• #mds
• #high_risk_mds
• #hypomethylating_agents
• #hmas